Investigational drug · Phase 2
Extended Phase
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Polycythemia Vera (PV).
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3,241
Any phase or sponsor naming "Extended Phase"
First trial start
2025
Sep 23, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Extended Phase", any sponsor or status.
Conditions studied
As listed on its trial records.
- Polycythemia Vera (PV)
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Extended Phase" as an intervention, largest first.
- Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and OlderPivotal-lookingTerminated
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT04904549 · 23,670 participants · Start May 26, 2021 · Primary completion Aug 31, 2024
Drug: SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series); SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series) and 3 more · For: COVID-19
Sites: Birmingham, Alabama; Huntsville, Alabama; Rolling Hills Estates, California · 86 sites in all
- A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)Pivotal-lookingTerminated
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00529373 · 16,071 participants · Start Sep 13, 2007 · Primary completion Nov 14, 2012
Drug: Odanacatib; Placebo for Odanacatib · For: Postmenopausal Osteoporosis
- Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef OutcomesPivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06008756 · 14,550 participants (planned) · Start Oct 9, 2023 · Primary completion Nov 29, 2029
Drug: Enlicitide Decanoate; Placebo · For: Arteriosclerosis; Hypercholesterolaemia
Sites: Alexander City, Alabama; Birmingham, Alabama; Daphne, Alabama · 669 sites in all
- An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 StudyPivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06534892 · 10,212 participants · Start Aug 1, 2024 · Primary completion Sep 30, 2026
Drug: RSVPreF3 OA vaccine · For: Respiratory Syncytial Virus Infections
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 251 sites in all
- Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01327846 · 10,066 participants · Start Apr 11, 2011 · Primary completion Mar 28, 2017
Drug: Canakinumab; Placebo and 1 more · For: Atherosclerosis
Sites: Athens, Alabama; Birmingham, Alabama; Fairhope, Alabama · 1,131 sites in all
- Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-028, 029 or 030 (NCT00197210)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00329745 · 8,687 participants · Start Jan 2007 · Primary completion Jul 2008
Drug: Rotarix™; Placebo · For: Infections, Rotavirus
Sites: Singapore, Singapore · 4 sites in all
- Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)Pivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT00549757 · 8,606 participants · Start Oct 2007 · Primary completion Feb 2013
Drug: Aliskiren; Placebo · For: Type 2 Diabetes Mellitus; Cardiovascular Disease
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 776 sites in all
- Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)Pivotal-lookingActive, not recruiting
Currax PharmaceuticalsIndustry
NCT06098079 · 8,600 participants (planned) · Start Jan 3, 2024 · Primary completion Jan 2029
Drug: Naltrexone-Bupropion (NB) Combination; Placebo · For: Obesity
Sites: Birmingham, Alabama; Cullman, Alabama; Mobile, Alabama · 140 sites in all
- Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)Pivotal-lookingCompleted
Portola PharmaceuticalsIndustry
NCT01583218 · 7,513 participants · Start Mar 2012 · Primary completion Dec 2015
Drug: Betrixaban; Enoxaparin · For: Venous Thromboembolism (VTE)
Sites: Birmingham, Alabama; Bakersfield, California; Fresno, California · 462 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT02842086 · 5,399 participants · Start Sep 2, 2016 · Primary completion Jan 31, 2019
Drug: F/TAF; F/TDF and 2 more · For: Pre-Exposure Prophylaxis of HIV-1 Infection
Sites: Beverly Hills, California; Los Angeles, California; Newport Beach, California · 93 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Respiratory-Resolved Isotropic 3D T1 Mapping of the Carotid Vessel Wall With B1 + Correction (CARISMAT1C).
Montón Quesada I, Hirsch C, Calarnou P, et al. · Magn Reson Med 2027
- Incomplete Spoiling Correction for 3D T 1 Mapping.
Belsley G, Tyler DJ, Robson MD, et al. · Magn Reson Med 2026
- Near-metal MRI Using PETRA With Extended Phase Encoding and Compressed Sensing.
Özen AC, Stepanek T, Liu S, et al. · Invest Radiol 2026
- Grand-Canonical Path Reweighting for Constant-Potential Langevin Dynamics.
Zhang Y, Fu L, Jin B, et al. · J Chem Theory Comput 2026
- Effect of ipratropium bromide on the interfacial organization of model lung surfactant membranes.
Marczak M, Fontaine P, Batys P, et al. · Colloids Surf B Biointerfaces 2026
- T2 mapping of individual fascicles of the sciatic nerve at 7 T using multi-echo spin-echo.
Sleight E, Piredda GF, Grouiller F, et al. · MAGMA 2026
Also in development for Polycythemia Vera (PV)
- FlonoltinibPhase 34 trials
Chengdu Zenitar Biomedical Technology Co., Ltd · MF, MF,PMF,PPV-MF,PET-MF, Polycythemia Vera (PV)
- DISC-3405Phase 21 trial
Disc Medicine, Inc · Polycythemia Vera (PV)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.